Translations:Glucagon-like peptide-1/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
14,847 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 09:48, 11 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Glucagon-like peptide-1)
Endogenous GLP-1 is rapidly degraded primarily by [[dipeptidyl peptidase-4]] (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and [[renal clearance]], resulting in a [[half-life]] of approximately 2 minutes. Consequently, only 10–15 % of GLP-1 reaches circulation intact, leading to fasting plasma levels of only 0–15 pmol/L. To overcome this, [[GLP-1 receptor agonist]]s and [[DPP-4 inhibitors]] have been developed to increase GLP-1 activity. As opposed to common treatment agents such as [[insulin]] and [[sulphonylurea]], GLP-1-based treatment has been associated with [[weight loss]] and a lower risk of [[hypoglycemia]], two important considerations for patients with type 2 diabetes.

Endogenous GLP-1 is rapidly degraded primarily by dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and renal clearance, resulting in a half-life of approximately 2 minutes. Consequently, only 10–15 % of GLP-1 reaches circulation intact, leading to fasting plasma levels of only 0–15 pmol/L. To overcome this, GLP-1 receptor agonists and DPP-4 inhibitors have been developed to increase GLP-1 activity. As opposed to common treatment agents such as insulin and sulphonylurea, GLP-1-based treatment has been associated with weight loss and a lower risk of hypoglycemia, two important considerations for patients with type 2 diabetes.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Glucagon-like_peptide-1/4/en&oldid=127231"